Immunocore Limited
By
Immunocore Limited
Published: Sept. 21, 2017, 2:04 p.m.·
Tags:
Scientific research,
Research and development
$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV
Read More →
Page 1 of 1 · Total posts: 1
1